Robot‐assisted radical cystectomy in a patient with muscle‐invasive bladder cancer following radiotherapy for prostate cancer

Abstract

Abbreviations & Acronyms GCb = gemcitabine plus carboplatin IMRT = intensity-modulated radiation therapy MIBC = muscle-invasive bladder cancer NAC = neoadjuvant chemotherapy PC = prostate cancer POD = postoperative day QOL = quality of life RARC = robot-assisted radical cystectomy RARP = robotic-assisted radical prostatectomy RC = radical cystectomy RT = radiotherapy Correspondence: ShingoIntroduction: Muscle-invasive bladder cancer following radiotherapy for prostate cancer is rare. We reported a case of muscle-invasive bladder cancer who underwent robot-assisted radical cystectomy following radiotherapy for prostate cancer. Case presentation: A 72-year-old man was referred to our division with a muscleinvasive bladder cancer. He had a history of intensity-modulated radiation therapy for localized prostate cancer. After three courses of platinum-based neoadjuvant chemotherapy, he obtained a radiologic complete response. He elected for robotassisted radical cystectomy, standard lymph node dissection, and intracorporeal ileal conduit urinary diversion. Pathological findings revealed no residual tumor within the bladder and residual tumor in the prostate. He had discharged without any complications; and quality of life had improved. Conclusion: A robot-assisted approach might be a potential option for well-selected patients with muscle-invasive bladder cancer who have previously received radiotherapy for localized prostate cancer.Although surgical treatment for patients with MIBC who have previously received RT for PC is challenging, this report indicates a robot-assisted approach might be a potential option for well-selected patients with MIBC who have previously received RT for localized PC.

Alisma orientale extract inhibits cell proliferation by promoting oxidative stress and apoptosis in prostate cancer cells

“…Currently, the conventional treatment approaches for prostate cancer encompass surgery, radiotherapy and chemotherapy, among others, but these modalities have inherent limitations [2]. As a result, researchers have begun to explore targeted therapies for prostate cancer [14]. Drugbased treatment for prostate cancer predominantly involves endocrine drugs [14].…”

“…As a result, researchers have begun to explore targeted therapies for prostate cancer [14]. Drugbased treatment for prostate cancer predominantly involves endocrine drugs [14]. Among these, antiandrogen drugs such as bicalutamide, nilumide and flutamide are commonly used and function by impeding the action of endogenous androgens on prostate cells, thereby delaying the growth or inducing apoptosis in prostate cancer cells [15].…”

“…Additionally, Chinese medicine generally exerts minimal harm on healthy cells, avoiding further damage to physical strength during treatment. As the cancer is targeted by the drugs, the patient's physical strength gradually recovers, and immunity improves [2,14]. Studies have shown that alisma and its derivatives possess antitumor properties and the ability to affect the behavior of prostate cancer cells.…”